XML 47 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Development Stage Supplemental Equity Disclosure
 12 Months Ended
Dec. 31, 2011
Development Stage Supplemental Equity Disclosure [Abstract]  
Development Stage Supplemental Equity Disclosure

11.    Development Stage Supplemental Equity Disclosure

Summarized below are the Company’s equity (common stock and common stock options) transactions since the Company’s inception through December 31, 2011 (in thousands except per share data).

 

                                         

Type of Security

   Date of Issuance   Shares of
Common
Stock		     Dollar
Amount of
Consideration
($)		     Price per
Share or
Exercise
Price per
Share
($)		     Counter
Party to
Transaction		   Nature of
Non-Cash
Consideration		   Basis of
Assigning Cost

Common Stock

   April 3, 2006     1,624,278       2       0.002     Founders   NA   Cash

Common Stock

   January 8, 2007     7.040,318       48 (A)      0.007     CytRx   Contributed
Assets		   Predecessor
Cost

Common Stock

   April 30, 2007     3,273,292       15,348 (B)      5.19     CytRx   NA   Cash

Common Stock

   April 30, 2007     462,112       2,311       5.00     UMMS   Intellectual
Properties		   Independent
Third Party
Valuation

Common Stock

   August 18, 2007     30,000       150       5.00     Directors   —   Cash

Common Stock

   September 28, 2007     188,387       978       5.19     CytRx   NA   Independent
Third Party
Valuation

Common Stock

   November 21, 2007     66,045       331       5.00     Exercise of Stock
Options		   NA   Cash

Common Stock

   June 26, 2008     1,073,299       7,918       8.12     PIPE   NA   Net Cash

Common Stock

   October 6, 2008 and
November 16, 2008		     5,500       26       5.00     Exercise of Stock
Options		   NA   Cash

Common Stock

   January 30, 2009     58,398       NA       NA         NA   Market Value

Common Stock

   May 1, 2009     281       NA       4.19     Exercise of Stock
Options		   NA   Cash

Common Stock

   August 3, 2009 and
August 4, 2009		     2,385,715       7,714       3.50     Registered Direct   NA   Net Cash

Common Stock

   March 22, 2010     2,700,000       15,235       6.00     Registered Direct   NA   Net Cash

Common Stock

   Various — 2010     53,500       254       4.75     Exercise of Stock
Options		   NA   Cash

Common Stock

   January 2, 2010 and
February 9, 2010		     86,634       207       NA     Restricted Stock
Units		   NA   Market Value

Common Stock

   March 4, 2011     6,000,000       7,307       1.35     Registered Direct   NA   Net Cash

Common Stock

   March 15, 2011     220,729       256       1.16     Restricted Stock
Units		   NA   Market Value

Common Stock

   April 13, 2011     4,974,090       6,367       NA     Acquired Company   NA   Market Value

Common Stock

   April 20, 2011     11,950,000       10,853       1.00     Registered Direct   NA   Net Cash

Common Stock

   July 1, 2011     18,824       15       0.83     ESPP   NA   Cash

Common Stock

   July 27, 2011     150,000       150       1.00     Exercise of
Warrants		   NA   Cash

Common Stock

   September 26, 2011     700,000       455       0.65     Registered Direct   NA   Cash

Common Stock

   December 6, 2011     4,151,000       3,120       NA     Exchange with
Warrant Holders		   NA   Market Value

Common Stock

   Various — 2011     599,051       594       NA     Stock Compensation   NA   Market Value

 

(A) Transactions between related parties are accounted for at the historical cost of CytRx, with the intellectual property which was previously expensed on CytRx’s books being recorded at zero cost and equipment and furnishings being recorded at $48,000.

 

(B)

The Company received gross proceeds of $17.0 million for the issuance of the 3,273,292 shares of common stock which equals $5.19 per share. The gross proceeds were reduced by a reimbursement to CytRx of (1) $1.3 million for RXi’s pro rata share of offering costs related to the April 17, 2007 private placement conducted by CytRx to fund its capital contribution to the Company and (2) $363,000 of expenses incurred on behalf of RXi for the year ended December 31, 2006. Net proceeds to RXi after these charges were $15.3 million or $4.69 a share.